Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Berchuck, A. "Endometrial carcinoma and its precursors." Curr Ther Endocrinol Metab 6 (1997): 599-602. (Review)

Scholars@Duke

Berchuck, A, and Cirisano, F. "Genetics of ovarian cancer." Endocrinologist 7, no. 2 (1997): 103-106.

Scholars@Duke

Rubin, SC, Benjamin, I, Behbakht, K, Takahashi, H, Morgan, MA, LiVolsi, VA, Berchuck, A, Muto, MG, Garber, JE, Weber, BL, Lynch, HT, and Boyd, J. "Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1." N Engl J Med 335, no. 19 (November 7, 1996): 1413-1416.

Full Text

van den Brule, FA, Buicu, C, Berchuck, A, Bast, RC, Deprez, M, Liu, FT, Cooper, DN, Pieters, C, Sobel, ME, and Castronovo, V. "Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma." Human Pathology 27, no. 11 (November 1996): 1185-1191.

Full Text

Lancaster, JM, Brownlee, HA, Bell, DA, Futreal, PA, Marks, JR, Berchuck, A, Wiseman, RW, and Taylor, JA. "Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer." Molecular Carcinogenesis 17, no. 3 (November 1996): 160-162.

Full Text

Kohler, MF, Carney, P, Dodge, R, Soper, JT, Clarke-Pearson, DL, Marks, JR, and Berchuck, A. "p53 overexpression in advanced-stage endometrial adenocarcinoma." Am J Obstet Gynecol 175, no. 5 (November 1996): 1246-1252.

Scholars@Duke

Vaughn, JP, Cirisano, FD, Huper, G, Berchuck, A, Futreal, PA, Marks, JR, and Iglehart, JD. "Cell cycle control of BRCA2." Cancer Research 56, no. 20 (October 1996): 4590-4594.

Scholars@Duke

Risinger, JI, Umar, A, Boyd, J, Berchuck, A, Kunkel, TA, and Barrett, JC. "Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair." Nat Genet 14, no. 1 (September 1996): 102-105.

Full Text

Elbendary, AA, Cirisano, FD, Evans, AC, Davis, PL, Iglehart, JD, Marks, JR, and Berchuck, A. "Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells." Clin Cancer Res 2, no. 9 (September 1996): 1571-1575.

Scholars@Duke

Berchuck, A, Cirisano, F, Lancaster, JM, Schildkraut, JM, Wiseman, RW, Futreal, A, and Marks, JR. "Role of BRCA1 mutation screening in the management of familial ovarian cancer." AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 175, no. 3 (September 1996): 738-746.

Scholars@Duke

Pages